17 March 2026·PIB

Availability of generic medicines under PMBJKs

In this note

1. At a Glance

Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is a Department of Pharmaceuticals scheme that retails quality generic medicines at 50%-80% cheaper than branded equivalents through Jan Aushadhi Kendras (JAKs) [1][2].
Product basket: 2,110 medicines + 315 surgicals/consumables/devices across all major therapeutic groups (cardio, anti-cancer, anti-diabetic, anti-infectives, anti-allergic, GI, nutraceuticals) [1].
Implementing agency: Pharmaceuticals & Medical Devices Bureau of India (PMBI) — an autonomous society under Dept of Pharmaceuticals, Ministry of Chemicals & Fertilizers [4].
Relevance: GS-II (health, vulnerable sections), GS-III (pharma sector, IPR/generics).

PIB release dated 17 March 2026 (Dept of Pharmaceuticals) reaffirming product-basket size and awareness push [1].
Jan Aushadhi Diwas 2025 week-long celebrations flagged off by Union Minister J.P. Nadda in March 2025 [3].
Kendra count crossed 17,990 by 31 Dec 2025, up from 15,057 (28 Feb 2025) and 16,912 (30 June 2025) — rapid scale-up toward the 2027 target [2].

Launched November 2008 by Department of Pharmaceuticals as Jan Aushadhi Campaign; rebranded PMBJP in 2015–16 [4].
Implementing body reorganised — BPPI (Bureau of Pharma PSUs of India) renamed PMBI (Pharmaceuticals & Medical Devices Bureau of India) [4].
Milestones: 9,000+ stores covering 743/766 districts (2022) → 15,057 (Feb 2025) → 17,990 (Dec 2025) [2][4].
Cumulative citizen savings: ~₹23,000 cr in first 9 yrs; ~₹38,000 cr by June 2025 on MRP-equivalent sales of ₹7,700 cr [4].

Scheme: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) [1].
Outlets: Jan Aushadhi Kendras (JAKs) [1].
Nodal Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals [1].
Implementing Agency: PMBI (autonomous society under DoP) [4].
Launch year: 2008 (relaunched/rebranded 2015) [4].
Product basket: 2,110 drugs + 315 surgicals/consumables/devices [1].
Price discount: 50%-80% vs branded [1].
Kendras (31 Dec 2025): 17,990 [2].
Target: 25,000 JAKs by March 2027 [2].
Cumulative savings: ~₹38,000 cr (till June 2025) [4].

Economic

Reduces out-of-pocket health expenditure (~62% of total health spend in India) by substituting high-margin branded drugs with generics [1][4].
Cumulative consumer savings ~₹38,000 cr against ₹7,700 cr in MRP sales — a ~5x multiplier on consumer surplus [4].

Social

Targets affordability for BPL, elderly, chronic-disease patients (diabetes, CVD, cancer) — therapeutic groups explicitly covered [1].
Self-employment for pharmacists, SC/ST/Divyangjan, women entrepreneurs via preferential kendra allotment policies [4].

Administrative / Governance

Quality assured: every batch tested at NABL-accredited labs before supply to Kendras [1].
Awareness via IEC campaigns and Jan Aushadhi Diwas (7 March) annually [3].
Bottleneck: physician prescription bias toward branded drugs; uneven district-level kendra density.

Scientific / Technological

Leverages India's status as global generics hub ("pharmacy of the world"); aligns with Indian Pharmacopoeia standards [4].

March 2025: J.P. Nadda flags off Jan Aushadhi Diwas 2025 celebrations [3].
Feb 2025: 15,057 JAKs operational [2].
June 2025: 16,912 JAKs; cumulative savings ~₹38,000 cr [2][4].
Dec 2025: 17,990 JAKs [2].
March 2026 (PIB): Product basket reaffirmed at 2,110 drugs + 315 surgicals; awareness drives ongoing [1].

GS-II: Government policies & interventions for development in health sector; issues relating to poverty & hunger; vulnerable sections.
GS-III: Indian economy — pharmaceutical sector, IPR & generics.
Question stems: 1. "PMBJP has democratised access to medicines but acceptance remains the binding constraint." Examine. 2. Discuss the role of generic medicines in reducing out-of-pocket health expenditure in India, with reference to PMBJP. 3. Critically evaluate the institutional design of PMBI in delivering affordable healthcare under PMBJP.

Ayushman Bharat (PM-JAY) — complementary financial protection for hospitalisation.
National Pharmaceutical Pricing Authority (NPPA) & DPCO 2013 — price control on essential drugs.
National List of Essential Medicines (NLEM) 2022 — basis for price regulation overlap with PMBJP basket.
Production Linked Incentive (PLI) for Pharma & Bulk Drugs — supply-side support to APIs/KSMs.
TRIPS & Indian Patents Act 1970 (Sec 3(d)) — generics policy & evergreening jurisprudence.
Out-of-Pocket Expenditure & National Health Accounts — measures health affordability outcomes.
CDSCO / Drugs & Cosmetics Act, 1940 — regulatory backbone for drug quality.
Indian Pharmacopoeia Commission — quality standards for PMBJP procurement.

Wrong Ministry: PMBJP is under Chemicals & Fertilizers (Dept of Pharmaceuticals), NOT Ministry of Health & Family Welfare [1].
Wrong agency: PMBI implements it — not NPPA (pricing), not CDSCO (regulation), not BPPI (old name) [4].
Confusing with AMRIT (Affordable Medicines & Reliable Implants for Treatment) — a separate scheme run by HLL Lifecare under MoHFW.
Launch year: Original launch 2008; rebranded as PMBJP in 2015 — both can appear as decoys.
Discount band: 50%-80% (not "up to 90%"; not "at cost") [1].
Jan Aushadhi Diwas date: 7 March, not 1 March or 7 April [3].